TUBERCULOSIS

Definition of Tuberculosis
Tuberculosis is a chronic infection caused by the bacteria Mycobacterium tuberculosis (and occasionally other variants of Mycobacterium). It usually involves the lungs, but other organs of the body can also be involved.

Symptoms of Tuberculosis

Only about 10 percent of those infected with TB develop the disease. The first symptoms of an active case of TB may be so commonplace that they are often dismissed as the effects of a cold or flu. The individual may get tired easily, feel slightly feverish or cough frequently. It usually goes away by itself, but about in about half the cases, it will return. For people who have the disease, TB can cause lung or pleural (the lining of the lung) disease or it may spread through the body via the blood. Often people do not seek the advice of a doctor until they have pronounced symptoms, such as pleurisy (a sharp pain in the chest when breathing deeply or coughing) or the spitting up of blood. Neither of these symptoms is solely of tuberculosis, but they should not be ignored. Other symptoms include fever, loss of appetite, weight loss and night sweats. About 15 percent of people with the disease develop TB in an organ other than the lung, such as the lymph nodes, GI tract, and bones and joints.

Diagnosis of Tuberculosis

If a person has a significant reaction upon being tuberculin skin-tested for the first time, additional laboratory and x-ray examinations are necessary to determine if the individual has active TB. Tuberculosis can mimic other diseases, such as pneumonia, lung abscesses, tumors and fungal infections, or occur along with them. For a proper diagnosis, therefore, a doctor will rely on symptoms and other physical signs; a person's history of exposure to TB and x-rays that may show evidence of TB infection (usually in the form of lesions or cavities in the lungs). TB bacilli grown in cultures of sputum or other specimens provide a positive diagnosis.


Treatment of Tuberculosis

With treatment, the chances of full recovery is good. Although several treatment protocols for active TB are in wide use by specialists, and protocols sometimes change due to advanced in our understanding of optimal therapy, they generally share three principles:

  1. The regimen must include several drugs to which the organisms are susceptible.
  2. The patient must take the medication on a regular basis.
  3. Therapy must continue for a sufficient time.
Also, treatment recommendations are subject to change depending upon both the characteristics of the particular organism being treated and newer advances in therapeutic agents. Thus, consultation on treatment strategies with local public health and infectious disease experts is always advisable.
Isoniazid (INH) is one of the most common drugs used for TB. Inexpensive, effective and easy to take, it can prevent most cases of TB and, when used in conjunction with other drugs, cure most TB. INH preventive treatment is recommended for individuals who have:
  • close contact with a person with infectious TB
  • positive tuberculin skin test reaction and an abnormal chest x-ray that suggests inactive TB
  • a tuberculin skin test that converted from negative to positive within the past two
  • a positive skin test reaction and a special medical condition or who are on corticosteroid therapy
  • a positive skin test reaction, even with none of the above risk factors (in those under 35)
Isoniazid and rifampin are the keystones of treatment, but because of increasing resistance to them, pyrazinamide and either streptomycin sulfate or ethambutol HCL are added to regimens. If the patient is unable to take pyrazinamide, a nine-month regimen of isoniazid and rifampin is recommended. Even if susceptibility testing reveals that the patient is infected with an isoniazid-resistant strain, the isoniazid component is continued because some organisms may yet be sensitive. In addition, two drugs to which the organisms are likely to be sensitive also are incorporated into the regimen. The beginning phase of treatment is crucial for preventing the emergence of drug resistance and ensuring a good outcome. Six months is the minimum acceptable duration of treatment for all adults and children with culture-positive TB. Drug resistance may be either primary or acquired. Primary resistance occurs in patients who have had no previous antimycobacterial treatment. Acquired resistance occurs in patients who have been treated in the past, and it is usually is a result of non-adherence to the recommended regimen or incorrect prescribing. It has been estimated that one in seven cases of tuberculosis is resistant to drugs that previously cured the disease. Resistance arises when patients fail to complete their drug therapy, lasting six months or longer. The hardiest TB bacteria are allowed to survive as a result, and as they multiply, they spread their genes to a new generation of bacteria - and to new victims. The drug-resistant forms of TB that do not respond to the usual drug therapy might be treatable by other, sometimes more toxic drugs. Officials of the Center for Disease Control and Prevention call for aggressive intervention to prevent the further spread of drug-resistant TB, including finding 'every TB patient' and ensuring that patients complete their drug therapy. To accomplish this, increasing use of directly observed therapy (DOT) is being used - that is, the actual, documented observation of the patient when he or she takes the medicine. This method has been shown to reduce the likelihood of treatment failures.